mizagliflozin

01/01/2018 - "This study assessed the efficacy and safety of mizagliflozin in patients with functional constipation. "
01/01/2019 - "Mizagliflozin for the Treatment of Functional Constipation: Are New Drugs Better?"
07/05/2017 - "These results suggest the potential use of a novel selective SGLT1 inhibitor, mizagliflozin, for the amelioration of chronic constipation."
07/05/2017 - "Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation."
01/01/2018 - "The SGLT1 inhibitor mizagliflozin showed favourable efficacy and tolerability at 5 mg and 10 mg doses in patients with functional constipation, providing a potential alternative therapy to available drugs. "

10/01/2021 - "Mizagliflozin, a selective SGLT1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease."
10/01/2021 - "These results suggest that mizagliflozin and phlorizin can improve vascular cognitive impairment through the inhibition of neural SGLT1 and phlorizin also does so through the improvement of CBF in a mouse model of small vessel disease."
10/01/2021 - "We examined the effects of mizagliflozin, a selective SGLT1 inhibitor, and phlorizin, a non-selective SGLT inhibitor, on vascular cognitive impairment in a mouse model of small vessel disease. "

01/01/2019 - "Future Possibility of Mizagliflozin on Functional Constipation and/or Irritable Bowel Syndrome With Constipation."

01/01/2018 - "The most common adverse events were nasopharyngitis (one [1%] of 86 patients in the placebo group, seven [8%] of 85 on mizagliflozin 5 mg, and five [6%] of 86 on mizagliflozin 10 mg), diarrhoea (none on placebo, four [5%] patients on mizagliflozin 5 mg, and eight [9%] on mizagliflozin 10 mg), and abdominal distention (three [3%] on placebo, four [5%] on mizagliflozin 5 mg, and seven [8%] on mizagliflozin 10 mg). "

10/01/2023 - "Both mizagliflozin and KGA-2727 inhibited the growth of breast cancer cell lines. "
10/01/2023 - "We then administered mizagliflozin and KGA-2727, SGLT1 specific inhibitors to MCF-7 and MDA-MB-468 breast carcinoma cell lines, and their growth-inhibitory effects were examined. "